“Retirement Secret” Showed 995% Gain Last Time We Shared It

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

Luisa Salter-Cid net worth and biography

Luisa Salter-Cid Biography and Net Worth

Insider of Gossamer Bio

Luisa Salter-Cid, Ph.D., M.Sc., is the Chief Scientific Officer at Pioneering Medicines, a division of life sciences company Flagship Pioneering. Before this, she served at Chief Scientific Officer at Gossamer Bio where she established a large research team and clinical portfolio that was integral in the company’s IPO in 2019. Prior to Gossamer Bio, Dr. Salter-Cid served as Vice President at Bristol-Myers Squibb, heading the immunology, small molecule immuno-oncology and genomics teams. Presently, Dr. Salter-Cid serves on the Board of Directors for Jounce Therapeutics and is a member of the Scientific Advisory Boards of both Prometheus Biosciences and Enterome. She has authored over 80 publications and patents, and received her doctorate in immunology from the University of Miami.

What is Luisa Salter-Cid's net worth?: The estimated net worth of Luisa Salter-Cid is at least $138,063.55 as of March 23rd, 2021. Dr. Salter-Cid owns 206,065 shares of Gossamer Bio stock worth more than $138,064 as of April 26th. This net worth evaluation does not reflect any other assets that Dr. Salter-Cid may own. Learn More about Luisa Salter-Cid's net worth.
How do I contact Luisa Salter-Cid?: The corporate mailing address for Dr. Salter-Cid and other Gossamer Bio executives is 3013 SCIENCE PARK, SAN DIEGO CA, 92121. Gossamer Bio can also be reached via phone at (858) 684-1300 and via email at [email protected]. Learn More on Luisa Salter-Cid's contact information.
Has Luisa Salter-Cid been buying or selling shares of Gossamer Bio?: Luisa Salter-Cid has not been actively trading shares of Gossamer Bio during the last quarter. Most recently, Luisa Salter-Cid sold 5,491 shares of the business's stock in a transaction on Tuesday, March 23rd. The shares were sold at an average price of $9.48, for a transaction totalling $52,054.68. Following the completion of the sale, the insider now directly owns 206,065 shares of the company's stock, valued at $1,953,496.20. Learn More on Luisa Salter-Cid's trading history.
Who are Gossamer Bio's active insiders?: Gossamer Bio's insider roster includes Laura Carter (Insider), Bryan Giraudo (CFO), and Luisa Salter-Cid (Insider). Learn More on Gossamer Bio's active insiders.
Are insiders buying or selling shares of Gossamer Bio?: During the last year, Gossamer Bio insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $112,000.00. During the last year, insiders at the sold shares 4 times. They sold a total of 35,434 shares worth more than $42,022.32. The most recent insider tranaction occured on March, 27th when CFO Bryan Giraudo sold 6,430 shares worth more than $7,458.80. Insiders at Gossamer Bio own 9.5% of the company. Learn More about insider trades at Gossamer Bio.
Information on this page was last updated on 3/27/2024.

Luisa Salter-Cid Insider Trading History at Gossamer Bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/23/2021	Sell	5,491	$9.48	$52,054.68	206,065
8/29/2019	Sell	50,000	$19.88	$994,000.00

Luisa Salter-Cid Buying and Selling Activity at Gossamer Bio

Gossamer Bio Company Overview

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Today's Range

Now: $0.67

$0.63

$0.69

50 Day Range

MA: $1.17

$0.67

$1.51

2 Week Range

Now: $0.67

$0.45

$1.88

Volume

2,484,342 shs

Average Volume

1,197,531 shs

Market Capitalization

$151.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71